X

Drug Profile

Anti-MUC16 monoclonal antibody - Quest PharmaTech/AmrutBio

Alternative Names: Anti-MUC16 AR9.6; Anti-MUC16 mAb - Quest PharmaTech; AR 9.6; mAb-AR9.6

Latest Information Update: 12 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Nebraska Medical Center
Developer Quest PharmaTech
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

10 Jul 2023 Aanti-MUC16 monoclonal antibody is still in preclinical phase for Cancer in USA
10 Jul 2023 Quest PharmaTech has patent protection for Anti-MUC16 in USA
28 Oct 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com